Cargando…

Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art

Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer...

Descripción completa

Detalles Bibliográficos
Autores principales: Silveira, Celeste, Guedes, Renato, Maia, Diana, Curral, Rosário, Coelho, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933139/
https://www.ncbi.nlm.nih.gov/pubmed/31805761
http://dx.doi.org/10.30773/pi.2019.0106
_version_ 1783483145026273280
author Silveira, Celeste
Guedes, Renato
Maia, Diana
Curral, Rosário
Coelho, Rui
author_facet Silveira, Celeste
Guedes, Renato
Maia, Diana
Curral, Rosário
Coelho, Rui
author_sort Silveira, Celeste
collection PubMed
description Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain’s lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals’ well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities.
format Online
Article
Text
id pubmed-6933139
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Neuropsychiatric Association
record_format MEDLINE/PubMed
spelling pubmed-69331392020-01-02 Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art Silveira, Celeste Guedes, Renato Maia, Diana Curral, Rosário Coelho, Rui Psychiatry Investig Review Article Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain’s lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals’ well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities. Korean Neuropsychiatric Association 2019-12 2019-12-09 /pmc/articles/PMC6933139/ /pubmed/31805761 http://dx.doi.org/10.30773/pi.2019.0106 Text en Copyright © 2019 Korean Neuropsychiatric Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Silveira, Celeste
Guedes, Renato
Maia, Diana
Curral, Rosário
Coelho, Rui
Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title_full Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title_fullStr Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title_full_unstemmed Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title_short Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
title_sort neuropsychiatric symptoms of multiple sclerosis: state of the art
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933139/
https://www.ncbi.nlm.nih.gov/pubmed/31805761
http://dx.doi.org/10.30773/pi.2019.0106
work_keys_str_mv AT silveiraceleste neuropsychiatricsymptomsofmultiplesclerosisstateoftheart
AT guedesrenato neuropsychiatricsymptomsofmultiplesclerosisstateoftheart
AT maiadiana neuropsychiatricsymptomsofmultiplesclerosisstateoftheart
AT curralrosario neuropsychiatricsymptomsofmultiplesclerosisstateoftheart
AT coelhorui neuropsychiatricsymptomsofmultiplesclerosisstateoftheart